Monoamine Oxidase Inhibition in Parkinson's Disease Treatment

Monoamine oxidase (MAO) inhibitors represent a cornerstone in the symptomatic management of Parkinson’s disease (PD) by slowing the enzymatic breakdown of dopamine and thereby prolonging its availability in the striatum. Selective inhibition of the MAO-B isoform offers both enhancement of dopaminergic transmission and a reduction in the formation of neurotoxic by-products such as hydrogen peroxide and aldehydes. Clinically, MAO-B inhibitors are employed as monotherapy in early PD and as adjuncts to levodopa in more advanced stages, yielding improvements in motor fluctuations and levodopa dose requirements. Beyond symptomatic benefit, evidence from preclinical and clinical studies suggests potential neuroprotective actions mediated through antioxidant pathways, mitochondrial stabilisation and modulation of apoptotic signalling. Recent advances span detailed mechanistic insights into drug-receptor interactions, large-scale safety profiling, and the exploration of novel chemical scaffolds, all of which reinforce the global significance of MAO-B inhibition in PD management and future disease-modification strategies.

Research from Nature Portfolio

Retrospective analysis of post-marketing safety reports has illuminated distinct adverse-event profiles among selegiline, rasagiline and safinamide. The study detected liver-related signals for selegiline and a tyramine reaction uniquely associated with rasagiline, whereas safinamide showed a notably lower incidence of REM sleep behaviour disorder. These real-world data underscore the importance of individualising MAO-B inhibitor choice according to patient comorbidities and risk factors.

Monoamine Oxidase Inhibition in Parkinson's Disease Treatment publication trend

The graph below shows the total number of articles in monoamine oxidase inhibition in parkinson's disease treatment across all publications each year (not limited to Nature Index journals).

Technical terms

Monoamine oxidase B (MAO-B): An enzyme in glial cells that degrades dopamine, making it a target for prolonging synaptic dopamine.

Dopamine: A neurotransmitter central to motor control and reward pathways; its deficiency underlies PD motor symptoms.

Trace amine-associated receptor 1 (TAAR1): A G-protein-coupled receptor that modulates monoamine release and may mediate enhancer effects of certain MAO-B inhibitors.

Unified Parkinson’s Disease Rating Scale (UPDRS): A composite clinical tool for quantifying motor impairment, activities of daily living and complications in PD.

Neuroprotection: Strategies aimed at preserving neuronal integrity and function, often via antioxidant, anti-apoptotic or mitochondrial stabilisation mechanisms.

References

1. Striking Neurochemical and Behavioral Differences in the Mode of Action of Selegiline and Rasagiline. International Journal of Molecular Sciences (2023).
2. Efficacy and safety of selegiline for the treatment of Parkinson's disease: A systematic review and meta-analysis. Frontiers in Aging Neuroscience (2023).
3. Safety comparisons among monoamine oxidase inhibitors against Parkinson’s disease using FDA adverse event reporting system. Scientific Reports (2023).
4. Computational exploration of acefylline derivatives as MAO-B inhibitors for Parkinson’s disease: insights from molecular docking, DFT, ADMET, and molecular dynamics approaches. Frontiers in Chemistry (2024).
5. Monoamine oxidase-B (MAO-B) inhibitors: implications for disease-modification in Parkinson’s disease. Translational Neurodegeneration (2013).
6. Rasagiline Exerts Neuroprotection towards Oxygen–Glucose-Deprivation/Reoxygenation-Induced GAPDH-Mediated Cell Death by Activating Akt/Nrf2 Signaling. Biomedicines (2024).